Home to one of the largest concentrations of life scientists in the UK
Aberdeen has world-renowned research institutions within the Life Sciences industry, including the James Hutton Institute, world-leading research institute for land, crops, water and the environment.
There are also nationally recognised enterprises based in Aberdeen; Novabiotics Ltd, which was named Investment of the Year at the Scottish Enterprise Life Science Awards, whilst Ripptide Pharma Ltd was awarded Innovation of the Year at the Scottish Enterprise Life Science Awards in 2015.
In 2015, there were 900 people employed within Life Science industries in the Aberdeen City Region, within 60 Enterprises. Life Science industries in Aberdeen City and Aberdeenshire contributed £39.9million Gross Value Added to the Scottish economy in 2012.
Bio-Therapeutics Hub for Innovation
Growing the life sciences sector is a regional economic priority and will contribute to the Scottish and UK sector targets for innovation, collaboration and commercialisation.
The 69,000 sq ft Bio-therapeutics Hub for Innovation will be a focal point for sector ambition and growth. It will include accommodation for spin-outs, start-ups and established companies; collaboration space; and shared facilities for events, small conferences and networking. Its sector-specific support programmes will include incubation, acceleration, mentoring, commercialisation and growth planning. The hub will also act as a catalyst for international collaborations and investment into research and companies.
The hub will ensure that company creation and growth in an entrepreneurial ecosystem accelerates innovation and collaboration, and anchors life sciences activity, employment and value in the region.
The project has been developed by the ONE Life Sciences sector board, University of Aberdeen, Robert Gordon University, NHS Grampian and Scottish Enterprise and the ONE team is leading its delivery. The hub will be located on the Foresterhill Health Campus in Aberdeen - one of Europe’s largest integrated clinical, research and teaching sites.
Following approval of the detailed business case via the Aberdeen City Region Deal and procurement, a design team has been appointed to support the delivery of the project with a target of opening in December 2020. A planning application for the hub will be submitted in spring 2019 and construction is scheduled to start later that year.
There is an established life sciences strength in the North East Scotland with £160m GVA generated and 2,500 people employed, with 900 of those in 30 businesses that make up the current company cluster. More than £530m of research funding and company investment has been raised in the past five years.
The regional asset base comprises strong academic, clinical and research elements across the University of Aberdeen, Robert Gordon University, James Hutton Institute and NHS Grampian. The region is focussed on the high value end of research and development, including biologics, healthcare solutions, imaging, and digital healthcare. Aberdeen is one of the UK’s two biologics research and development clusters – alongside Cambridge. These regional assets and sector specialisms uniquely position Aberdeen at the forefront of developing the next generation of therapies and healthcare solutions for modern epidemics including cancer, dementia, diabetes and obesity. Download our Life Sciences sector overview.